Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Importance Prostate cancer is the second leading cause of cancer death among US men.
Objective To systematically review evidence on prostate-specific antigen (PSA)–based …

Background Robust data on patient-reported outcome measures comparing treatments for
clinically localized prostate cancer are lacking. We investigated the effects of active …

Background After 11 years of follow-up, the European Randomized Study of Screening for
Prostate Cancer (ERSPC) reported a 29% reduction in prostate-cancer mortality among men …

Background: Screening can detect prostate cancer at earlier, asymptomatic stages, when
treatments might be more effective. Purpose: To update the 2002 and 2008 US Preventive …

Methods The Canadian Task Force on Preventive Health Care is an independent panel of
volunteer clinicians and methodologists that makes recommendations about clinical …

Background For men with localised prostate cancer, surgery provides a survival benefit
compared with watchful waiting. Treatments are associated with morbidity. Results for …

Context Sexual function is the health-related quality of life (HRQOL) domain most commonly
impaired after prostate cancer treatment; however, validated tools to enable personalized …

Objective To explore ongoing symptoms, unmet needs, psychological wellbeing, self‐
efficacy and overall health status in survivors of prostate cancer. Patients and Methods An …

Introduction Decrements in health-related quality of life (HRQOL) and sexual difficulties are
a recognized consequence of prostate cancer (PCa) treatment. However little is known …